文献速递胸部肿瘤

血清蛋白质组学与血浆纤蛋白-3在间皮瘤鉴别中的前瞻性验证

Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases.
PubMed 文献 · J Thorac Oncol · 2021-06-09

该多中心前瞻性研究纳入638例疑似胸膜恶性肿瘤患者和110例石棉暴露对照,评估SOMAscan血清蛋白质组学和血浆纤蛋白-3(fibulin-3)鉴别恶性胸膜间皮瘤(MPM)的诊断性能,并与间皮素(mesothelin)比较。SOMAscan可区分MPM与石棉暴露对照(验证队列AUC 0.855),但对非MPM疑似患者无用;纤蛋白-3敏感性极低且劣于间皮素。结论:SOMAscan或可用于未来石棉暴露人群筛查,但两者均不应用于诊断或路径分层。

要点

  • SOMAscan区分MPM与石棉暴露对照验证队列AUC 0.855,但无法区分非MPM疑似患者。
  • 纤蛋白-3在95%特异性下敏感性仅7.4%和11.9%,均劣于间皮素。
  • SOMAscan蛋白与炎症标志物相关,但与石棉暴露及肿瘤体积无关。

核心结论

  • SOMAscan可能作为未来石棉暴露人群的MPM筛查工具,但纤蛋白-3和SOMAscan均不应用于诊断或路径分层。

研究设计与样本

  • 多中心前瞻性观察性研究,纳入22个中心,生成大型意向诊断队列,采血、处理和诊断评估标准化并随访1年。

主要发现

  • SOMAscan区分MPM与石棉暴露对照:敏感性75%,特异性88.2%,验证队列AUC 0.855。
  • SOMAscan在鉴别非MPM疑似胸膜恶性肿瘤患者中无用。
  • 纤蛋白-3(BosterBio)在MPM vs 非MPM疑似患者中敏感性7.4%(95%特异性),AUC 0.611(0.557-0.664),p=0.0015。
  • 纤蛋白-3在MPM vs 石棉暴露对照中敏感性11.9%(95%特异性),AUC 0.516(0.443-0.589),p=0.671。
  • 纤蛋白-3诊断性能劣于间皮素;SOMAscan蛋白与炎症标志物相关,但与石棉暴露及肿瘤体积无关。

关键数值与推荐

  • SOMAscan区分MPM与石棉暴露对照的验证队列AUC为0.855。
  • 纤蛋白-3在95%特异性下,MPM vs 非MPM疑似患者敏感性7.4%,MPM vs 石棉暴露对照敏感性11.9%。

临床怎么用

  • SOMAscan暂不用于临床诊断或路径分层,仅作为未来筛查研究的候选工具。
  • 纤蛋白-3不应用于MPM的诊断或鉴别诊断。

局限性

  • CloudClone纤蛋白-3检测未通过验证,改用BosterBio检测。
  • SOMAscan在非MPM疑似患者中无用,限制其鉴别诊断价值。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Malignant pleural mesothelioma (MPM) is difficult to diagnose. An accurate blood biomarker could prompt specialist referral or be deployed in future screening. In earlier retrospective studies, SOMAscan proteomics (Somalogic, Boulder, CO) and fibulin-3 seemed highly accurate, but SOMAscan has not been validated prospectively and subsequent fibulin-3 data have been contradictory. METHODS: A multicenter prospective observational study was performed in 22 centers, generating a large intention-to-diagnose cohort. Blood sampling, processing, and diagnostic assessment were standardized, including a 1-year follow-up. Plasma fibulin-3 was measured using two enzyme-linked immunosorbent assays (CloudClone [used in previous studies] and BosterBio, Pleasanton, CA). Serum proteomics was measured using the SOMAscan assay. Diagnostic performance (sensitivity at 95% specificity, area under the curve [AUC]) was benchmarked against serum mesothelin (Mesomark, Fujirebio Diagnostics, Malvern, PA). Biomarkers were correlated against primary tumor volume, inflammatory markers, and asbestos exposure. RESULTS: A total of 638 patients with suspected pleural malignancy (SPM) and 110 asbestos-exposed controls (AECs) were recruited. SOMAscan reliably differentiated MPM from AECs (75% sensitivity, 88.2% specificity, validation cohort AUC 0.855) but was not useful in patients with differentiating non-MPM SPM. Fibulin-3 (by BosterBio after failed CloudClone validation) revealed 7.4% and 11.9% sensitivity at 95% specificity in MPM versus non-MPM SPM and AECs, respectively (associated AUCs 0.611 [0.557-0.664], p = 0.0015) and 0.516 [0.443-0.589], p = 0.671), both inferior to mesothelin. SOMAscan proteins correlated with inflammatory markers but not with asbestos exposure. Neither biomarker correlated with tumor volume. CONCLUSIONS: SOMAscan may prove useful as a future screening test for MPM in asbestos-exposed persons. Neither fibulin-3 nor SOMAscan should be used for diagnosis or pathway stratification.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Tsim S, Alexander L, Kelly C, et al. Serum Proteomics and Plasma Fibulin-3 in Differentiation of Mesothelioma From Asbestos-Exposed Controls and Patients With Other Pleural Diseases. J Thorac Oncol. 2021. PMID: 34116230. doi:10.1016/j.jtho.2021.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。